Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study
Ayad K. Ali, Balraj S Heran, Mahyar Etminan
Pharmacotherapy2015
Summary (paraphrased)
Mining US FDA adverse-event reports (1998–2013) for men aged 18–45 on low-dose (1 mg) finasteride, the authors applied disproportionality analysis to detect signals for persistent sexual dysfunction and suicidal ideation. Of 4,910 reports, 577 described persistent sexual dysfunction and 39 described suicidal ideation; nearly 90% of the suicidal-ideation cases also reported sexual dysfunction, and most events were rated serious (death, hospitalization, or disability). The study provided early quantitative backing for the persistent-sexual-dysfunction signal specifically in young hair-loss patients.
Why it’s in the corpus
Early quantitative signal for persistent sexual dysfunction and suicidality in young low-dose finasteride users — the pharmacovigilance evidence base underlying later regulatory label changes.
Related records
- Peer-reviewed paper
Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase
Nguyen, David-Dan; et al. · Journal of the American Academy of Dermatology (research letter)
A WHO VigiBase case/non-case disproportionality study focused on finasteride and sexual dysfunction in young men treated for hair loss. Building on the same group's JAMA Dermatology work on finasteride and suicidality/depression, it identified about 7,700…
LIT-0772022-03PFSLiterature sweep · Oct 2026 - Peer-reviewed paper
How routine pharmacovigilance failed to identify finasteride's persistent sexual side effects
Michael S. Irwig · Andrology · 10:207-208
This opinion article examined how Merck and the US FDA handled signals of persistent sexual adverse effects of finasteride, noting the first regulatory warnings in Sweden (2008) and the UK (2009) and two independent groups' peer-reviewed reports of persistent…
LIT-0032022PFSLiterature sweep · Oct 2026 - Peer-reviewed paper
Isotretinoin-related adverse sexual and reproductive outcomes: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)
Cansu Altınöz Güney; Huriye Aybüke Koç · Cutaneous and Ocular Toxicology
Using FAERS data from 2004-2024 via the public dashboard and OpenVigil 2.1, the authors pulled isotretinoin-related adverse events and ran disproportionality analyses (PRR, ROR with 95% CIs, Evans' criteria) across four MedDRA system organ classes. From…
LIT-0392025PFSPSSDPRSDLiterature sweep · Oct 2026